An observational study in Dysmenorrhea, Heavy Menstrual Bleeding and Menorrhagia, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Assiut University · Observational
Menstrual disorders, particularly dysmenorrhea (painful menstruation) and heavy menstrual bleeding (excessive menstrual blood loss), are common conditions among young adult females that can substantially impact quality of life, university attendance, and academic performance. This study aims to evaluate the prevalence of heavy menstrual bleeding and determine the intensity of dysmenorrhea among undergraduate female medical students at Assiut University.
Participants in this cross-sectional observational study include nulliparous and nulligravid female undergraduate students enrolled in the Faculty of Medicine. Data collection involves face-to-face interviews and self-completed assessment instruments during non-instructional hours. Dysmenorrhea severity, pain characteristics, and related functional impairment are evaluated using the Working ability, Location, Intensity, Days of pain and Dysmenorrhea (WaLIDD) score. Menstrual blood volume is quantified using the Pictorial Blood Loss Assessment Chart (PBLAC) during the menstrual period to identify heavy menstrual bleeding. Additionally, the study assesses associated physical symptoms, academic absenteeism, and common pharmacological and non-pharmacological management strategies utilized by the participants.
398 studies on the registry are indexed under Dysmenorrhea; 96 are open to participants now.
This study's planned enrollment of 486 is above the median of 123 across 56 observational studies indexed under Dysmenorrhea.
Browse Dysmenorrhea studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Undergraduate female medical students enrolled in the Faculty of Medicine at Assiut University, Assiut, Egypt. Eligible participants are nulliparous and nulligravid female students recruited on campus during non-learning hours to complete face-to-face interviews and menstrual symptom assessments.
Exclusion Criteria:
Nulliparous and nulligravid undergraduate female students enrolled in the Faculty of Medicine at Assiut University. Participants complete an adapted semi-structured questionnaire incorporating the Working ability, Location, Intensity, Days of pain and Dysmenorrhea (WaLIDD) scale to assess dysmenorrhea severity, associated symptoms, academic impact, and management practices. In addition, participants evaluate menstrual blood loss during their menstrual cycle using the Pictorial Blood Loss Assessment Chart (PBLAC) to determine the prevalence of heavy menstrual bleeding. No therapeutic or experimental intervention is administered.
Dysmenorrhea Severity Assessed by the WaLIDD Score
Assessed using the Working ability, Location, Intensity, Days of pain and Dysmenorrhea (WaLIDD) score. The instrument evaluates 4 domains: study/work ability (0 to 3), anatomical pain locations (0 to 3), pain intensity (0 to 3), and duration of pain in days (0 to 3). The total score ranges from 0 to 12 points, categorized as follows: 0 indicates no dysmenorrhea, 1 to 4 indicates mild dysmenorrhea, 5 to 7 indicates moderate dysmenorrhea, and 8 to 12 indicates severe dysmenorrhea. Higher scores reflect greater symptom severity and functional impairment.
Time frame: Baseline
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University